Cargando…

Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink

OBJECTIVES: To estimate the 12-month probabilities of major adverse cardiovascular events (MACE) and non-cardiovascular death in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL-C). DESIGN: A retrospective database analysis. SETTING:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Christopher Ll, Durand, Adeline, McCormack, Terry, Hughes, Elizabeth, Berni, Thomas R, Lahoz, Raquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689406/ https://www.ncbi.nlm.nih.gov/pubmed/38030254 http://dx.doi.org/10.1136/bmjopen-2022-064541

Ejemplares similares

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
por: Wang, Kexin, et al.
Publicado: (2022)

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
por: McCormack, Terry, et al.
Publicado: (2016)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Trajectory of low-density lipoprotein cholesterol in patients with chronic kidney disease and its association with cardiovascular disease
por: Wang, Shih-Wei, et al.
Publicado: (2022)

Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes
por: Schmidt, Amand F., et al.
Publicado: (2023)

Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink
por: Lahoz, Raquel, et al.
Publicado: (2020)

Prognostic Role of Neutrophil to High-Density Lipoprotein Cholesterol Ratio for All-Cause and Cardiovascular Mortality in the General Population
por: Jiang, Ming, et al.
Publicado: (2022)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

ODP138 Age-related Associations of LDL Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-based Cohort Study
por: Kim, Min-Ju, et al.
Publicado: (2022)

The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease
por: Smeets, Diede, et al.
Publicado: (2022)

The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population
por: Huang, Yu, et al.
Publicado: (2023)

Association between extremely high-density lipoprotein cholesterol and adverse cardiovascular outcomes: a systematic review and meta-analysis
por: Zhang, Guanwei, et al.
Publicado: (2023)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Remnant cholesterol is associated with cardiovascular mortality
por: Zhang, Kerui, et al.
Publicado: (2022)

Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges
por: Tintut, Yin, et al.
Publicado: (2018)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Management of High Cardiovascular Risk in Diabetic Patients: Focus on Low Density Lipoprotein Cholesterol and Appropriate Drug Use in General Practice
por: Rottura, Michelangelo, et al.
Publicado: (2021)

The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension
por: Cheng, Qi, et al.
Publicado: (2021)

Association Between Periodontal Disease and Atherosclerotic Cardiovascular Diseases: Revisited
por: Zardawi, Faraedon, et al.
Publicado: (2021)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
por: Lütjohann, Dieter, et al.
Publicado: (2023)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem
por: Gidding, Samuel S., et al.
Publicado: (2019)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview
por: Wu, Min, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
por: Finney, Alexandra C., et al.
Publicado: (2023)

Common variable immunodeficiency—an independent risk factor for atherosclerotic cardiovascular diseases
por: Mattila, Juho, et al.
Publicado: (2023)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low‐Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients
por: Okerson, Ted, et al.
Publicado: (2017)

The formation and consequences of cholesterol-rich deposits in atherosclerotic lesions
por: Maxfield, Frederick R., et al.
Publicado: (2023)

The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting
por: Tani, Shigemasa
Publicado: (2020)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol
por: Roy, Satyajeet
Publicado: (2014)

Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy
por: Chiang, John Y. L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lk9ja2dkjr1qn71d008qolhr3n